Treating severe depression in days with brain stimulation

How far are we from fast, targeted brain stimulation becoming a standard treatment for severe depression?

In the US, the FDA cleared the Magnus Neuromodulation System with SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) for adults with depression who have not improved on antidepressants, on 1 September 2022. Standard repeated magnetic stimulation has been cleared for depression since 2008, but it uses a different protocol. The fast protocol rests on small trials, including a 2026 sham-controlled trial of 48 people with a one-month outcome. Access and payer coverage are not yet established, and it is not yet shown whether the effect lasts.

AI illustration · Illustrative scene, not a photograph of the specific device or experiment.
WHERE WE AREPilots

Close. Early pilots are running in the real world.

SAINT has FDA clearance for adults with depression who have not improved on antidepressants. The evidence comes from small trials, and the sources read include no independent multi-site trial with follow-up beyond about one month. That fits a pilot stage. It is not yet scaling or widespread, and no NICE guidance covering SAINT was found.

The tech tree

Everything recorded on Vrulum that this future needs, oldest foundations at the top and the goal at the bottom. Lines show what each step requires.

What it takes: Treating severe depression in days with brain stimulation Unlocked Being researched Locked
  1. 1998Adaptive deep brain stimulationCommercial Unlocked.
  2. 2017Accelerated transcranial magnetic stimulationCommercial Unlocked.
  3. 2021Focused ultrasound for the brainResearch and prototypes Being researched.
  1. 2008Standard repeated TMS authorised for depressionDone Unlocked.
  2. 2017Sham-controlled deep brain stimulation trialDone Unlocked.
  3. 2020Open-label trial of accelerated iTBS (SAINT)Done Unlocked.
  4. 2021Earlier double-blind sham-controlled SNT trialDone Unlocked.
  5. 2022FDA clearance for SAINT in treatment-resistant depressionDone Unlocked.
  6. 2024Meta-analysis of accelerated TMSDone Unlocked.
  7. 2026Sham-controlled SNT trial replicated at one monthDone Unlocked.
  8. Date not recordedMulti-site confirmation of SNT with longer follow-upNot started Locked.
  9. Date not recordedNHS guidance covering SAINTNot started Locked.
  1. GoalTreating severe depression in days with brain stimulationGoalRequires: Accelerated transcranial magnetic stimulation, Adaptive deep brain stimulation, Focused ultrasound for the brain, FDA clearance for SAINT in treatment-resistant depression, Standard repeated TMS authorised for depression, Open-label trial of accelerated iTBS (SAINT), Earlier double-blind sham-controlled SNT trial, Sham-controlled SNT trial replicated at one month, Meta-analysis of accelerated TMS, Sham-controlled deep brain stimulation trial, Multi-site confirmation of SNT with longer follow-up, NHS guidance covering SAINT. Locked.

The road so far

7 of 9 steps done.

  1. Done · 1 Sept 2022FDA clearance for SAINT in treatment-resistant depression

    The FDA cleared the Magnus Neuromodulation System with SAINT technology (510(k) K220177) on 1 September 2022, as substantially equivalent. The indication, as shown in a mirror of the FDA record, is adults with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medication in the current episode. [1][2]

  2. Done · 7 Oct 2008Standard repeated TMS authorised for depression

    The NeuroStar TMS System, a standard repeated transcranial magnetic stimulation device, was granted De Novo authorisation for the treatment of major depressive disorder (DEN070003, decision date 7 October 2008), as shown in a mirror of the FDA record. SAINT is a different device and protocol, so the 2008 authorisation does not cover it. [3]

  3. Done · Aug 2020Open-label trial of accelerated iTBS (SAINT)

    An open-label, single-arm study of 22 people with treatment-resistant depression (21 analysed) gave 50 intermittent theta-burst sessions over five days. 19 of 21 completers (90.5%) reached remission on the MADRS. It had no sham arm, a small sample and no follow-up beyond the end of treatment, so it shows feasibility and a signal, not a comparison with a control. [4]

  4. Done · Oct 2021Earlier double-blind sham-controlled SNT trial

    A double-blind, sham-controlled randomised trial of Stanford Neuromodulation Therapy randomised 29 people with treatment-resistant depression (14 active, 15 sham). The primary outcome was MADRS at four weeks: a mean reduction of 52.5% in the active group and 11.1% in the sham group. The abstract reports no p value. [5]

  5. Done · Feb 2026Sham-controlled SNT trial replicated at one month

    A double-blind, sham-controlled randomised trial in 48 people with treatment-resistant depression (24 active, 24 sham) reported one-month remission in 50.0% of the active group and 20.8% of the sham group (p = 0.035). The primary outcome was measured at one month only. [6]

  6. Done · 7 Feb 2024Meta-analysis of accelerated TMS

    A 2024 systematic review and meta-analysis of 14 studies (4 randomised trials and 10 controlled before-and-after studies) found no statistically significant difference between accelerated and standard TMS in three randomised trials (standardised mean difference -0.67, 95% CI -1.62 to 0.27, p = 0.16). The authors describe the included studies as generally low quality, with high heterogeneity (I² = 93%) and signs of publication bias for some comparisons. Follow-up in the included studies ran from three weeks to three months. [7]

  7. Done · Nov 2017Sham-controlled deep brain stimulation trial

    A multisite, randomised, sham-controlled trial of subcallosal cingulate deep brain stimulation in treatment-resistant depression (90 people randomised: 60 active, 30 sham) did not show a statistically significant difference in response, defined as at least 40% reduction, averaged over months 4 to 6: 20% (12/60) versus 17% (5/30). Deep brain stimulation needs surgery to implant electrodes. [8]

  8. Not startedMulti-site confirmation of SNT with longer follow-up

    The sources read include no multi-site, sham-controlled SNT or SAINT trial with follow-up beyond about one month. Published follow-up for accelerated TMS in the 2024 meta-analysis ran from about three weeks to three months. [6][7]

  9. Not startedNHS guidance covering SAINT

    NICE's guidance on repetitive TMS for depression (HealthTech guidance 396, published 16 December 2015, originally interventional procedures guidance IPG542) covers standard rTMS, not SAINT. No NICE guidance on SAINT was found in the sources read. [9]

Why it matters

A course that takes days rather than weeks could make treatment easier to start and to finish, which matters for people who have not improved on medicines. Whether it becomes standard depends on evidence that benefits last, on access beyond specialist clinics, and on whether payers cover it. One sham-controlled trial of deep brain stimulation, which needs surgery, did not show a significant effect.

What stands in the way

  • Most of the sham-controlled SNT evidence comes from small trials, with 48 or fewer people randomised, and the primary outcomes were measured at four weeks or one month.
  • Whether the effect lasts is not yet shown. Follow-up in the 2024 meta-analysis ran from three weeks to three months.
  • Accelerated TMS has not been shown to beat standard TMS. Three randomised trials found no significant difference between the two.
  • Access and payer coverage were not verified from payer or CMS documents, so it is unclear how widely SAINT can be used outside specialist sites.
  • No NHS or NICE guidance on SAINT was found, so UK access is unclear.
  • Trials use different outcome measures, such as remission on MADRS in some and response in others, so results cannot be compared directly.

Signals to watch

  • A multi-site, sham-controlled SNT or SAINT trial with follow-up beyond one month.
  • Results from research groups outside the Stanford-linked trials.
  • A UK health technology assessment of SAINT or other accelerated protocols.
  • Payer policies that extend coverage to more settings or to private insurers.
  • Regulatory decisions on deep brain stimulation for depression.

Sources

  1. government report
    510(k) K220177: Magnus Neuromodulation System (MNS) with SAINT Technology, Model 1001K
    U.S. Food and Drug Administration, 1 Sept 2022.
  2. other
    Magnus Neuromodulation System (MNS) with SAINT Technology, Model 1001K: 510(k) K220177 (mirror of FDA record with indication summary)
    Innolitics (mirror of the FDA 510(k) database), 1 Sept 2022.
  3. other
    De Novo DEN070003: NeuroStar TMS System (mirror of FDA De Novo record)
    RegDataLab (mirror of the FDA De Novo database), 7 Oct 2008.
  4. peer reviewed paper
    Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
    American Journal of Psychiatry, Aug 2020.
  5. peer reviewed paper
    Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
    American Journal of Psychiatry, Oct 2021.
  6. peer reviewed paper
    Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy
    World Psychiatry, Feb 2026.
  7. review article
    Short-term and long-term efficacy of accelerated transcranial magnetic stimulation for depression: a systematic review and meta-analysis
    Ruifeng Shi, Zuxing Wang, Dong Yang et al.. BMC Psychiatry, 7 Feb 2024.
  8. peer reviewed paper
    Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial
    The Lancet Psychiatry, Nov 2017.
  9. government report
    Repetitive transcranial magnetic stimulation for depression (HealthTech guidance 396)
    National Institute for Health and Care Excellence (NICE), 16 Dec 2015.

Last reviewed 21 Oct 2026.